Lenvervimab

Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.

[2] This drug is being developed by GC Pharma.

As of 2018[update], lenvervimab is undergoing Phase II/III trials.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.